Company Filing History:
2 out of 532 
2 out of 917 
2 out of 2,345 
Years Active: 2021-2024
Title: Zejuan Li: Innovator in Nanoparticle Delivery Systems for Cancer Treatment
Introduction
Zejuan Li is a prominent inventor based in Chicago, IL, known for his groundbreaking work in the field of cancer treatment. He holds 2 patents that focus on innovative methods for treating acute myeloid leukemia (AML) using advanced nanoparticle delivery systems. His contributions to medical science are significant, particularly in the area of targeted therapies.
Latest Patents
Li's latest patents include methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. This nanoparticle delivery system is designed for sustained delivery of microRNA-150 (miR-150) to FLT3-overexpressing AML cells. The delivery system comprises poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for the FLT3 receptor. These patents provide innovative methods for treating AML characterized by FLT3-overexpression.
Career Highlights
Throughout his career, Zejuan Li has worked with esteemed institutions such as the University of Cincinnati and the University of Chicago. His research has focused on developing effective treatment strategies for cancer, particularly through the use of nanoparticle technology.
Collaborations
Li has collaborated with notable colleagues in his field, including Jianjun Chen and Seungpyo Hong. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Zejuan Li's work in nanoparticle delivery systems represents a significant advancement in the treatment of acute myeloid leukemia. His innovative approaches and collaborations continue to pave the way for future breakthroughs in cancer therapy.